Changes and clinical significance of serum miR-155 and miR-205-5p expression levels in patients with hepatitis C virus infection

doi:10.11958/20231954

Abstract

Abstract:

Objective To investigate changes and clinical significance of serum microRNA-155 (miR-155) and microRNA-205-5p (miR-205-5p) levels in patients with hepatitis C virus (HCV) infection. Methods A total of 141 patients with HCV infection were collected and divided into the HCV-1b group (92 cases) and the non HCV-1b group (49 cases) according to their genotype, and another 141 healthy volunteers who underwent physical examinations in our hospital during the same period were collected as the control group. The general information, biochemical indicators and serum levels of miR-155 and miR-205-5p were compared between the three groups. According to the grading of hepatitis activity, HCV infected patients were classified into the G0, G1, G2, G3 and G4 groups, and serum levels of miR-155 and miR-205-5p were compared between the five groups. Receiver operating characteristics (ROC) curve was used to analyze clinical values of serum miR-155 and miR-205-5p in diagnosing hepatitis activity of G1-G4 in patients with HCV infection. Results The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) were obviously higher in the HCV-1b group and the non HCV-1b group than those in the control group, while the level of ALB was obviously lower than that in the control group (P<0.05). The serum level of miR-155 was increased in turn in the control group, the non-HCV-1b group and the HCV-1b group, and the serum level of miR-205-5p was decreased in turn (P<0.05). The serum level of miR-155 increased in turn with the increased grading of hepatitis activity, while the serum miR-205-5p level decreased in turn (P<0.05). The area under curve (AUC) values of serum miR-155, miR-205-5p and their combination in diagnosing hepatitis activity of G1-G4 in HCV infected patients were 0.855, 0.793 and 0.913, respectively, and the combination of the two is superior to each individual diagnosis (P<0.05). Conclusion The serum miR-155 level increases and miR-205-5p level decreases in HCV infected patients. The combination of the two has high efficacy in diagnosing hepatitis activity of G1-G4 in HCV infected patients.

Key words: hepacivirus, microRNAs, hepatitis C virus, miR-155, miR-205-5p, HCV-1b genotype, hepatitis activity

CLC Number:

R373.21，R512.63

Figures/Tables 5

References 21

[1]	Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020:a modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7(5):396-415. doi:10.1016/S2468-1253(21)00472-6.
[2]	ROGER S, DUCANCELLE A, LE GUILLOU-GUILLEMETTE H, et al. HCV virology and diagnosis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(3):101626. doi:10.1016/j.clinre.2021.101626.
[3]	TOMASIEWICZ K, FLISIAK R, JAROSZEWICZ J, et al. Recommendations of the polish group of experts for HCV for the treatment of hepatitis C in 2023[J]. Clin Exp Hepatol, 2023, 9(1):1-8. doi:10.5114/ceh.2023.125957.
[4]	孔琳玲, 张燕, 龚翔, 等. miR-122及miR-155水平在乙型肝炎相关慢加急性肝衰竭患者中表达及临床价值[J]. 现代消化及介入诊疗, 2022, 27(12):1523-1526.
	KONG L L, ZHANG Y, GONG X, et al. Clinical value of miR-122 and miR-155 levels in patients with hepatitis B-related cirrhosis[J]. Modern Interventional Diagnosis and Treatment in Gastroenterology, 2022, 27(12):1523-1526. doi:10.3969/j.issn.1672-2159.2022.12.007.
[5]	SUN Q, ZHANG X, TAN Z, et al. Bone marrow mesenchymal stem cells-secreted exosomal microRNA-205-5p exerts inhibitory effect on the progression of liver cancer through regulating CDKL3[J]. Pathol Res Pract, 2021,225:153549. doi:10.1016/j.prp.2021.153549.
[6]	中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版)[J]. 中华肝脏病杂志, 2015, 23(12):906-923.
	Chinese Society of Hepatology,Chinese Society of Infectious Diseases. The guideline of prevention and treatment for hepatitis C:a 2015 update[J]. Chin J Hepatol, 2015, 23(12):906-923. doi:10.3969/j.issn.1007-8134.2016.01.001.
[7]	中华医学会传染病与寄生虫病学分会, 中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华内科杂志, 2001, 40(1):62-68.
	Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology. Prevention and treatment of viral hepatitis[J]. Chin J Intern Med, 2001, 40(1):62-68. doi:10.3760/j.issn:1007-3418.2000.06.001.
[8]	ZHOU J, WANG F D, LI L Q, et al. Management of in- and out-of-hospital screening for hepatitis C[J]. Front Public Health, 2023,10:984810. doi:10.3389/fpubh.2022.984810.
[9]	杨艳艳, 白顺. 慢性丙型肝炎患者抗核抗体谱表达与HCV-RNA载量及HCV基因型的关联分析[J]. 临床输血与检验, 2022, 24(6):767-772.
	YANG Y Y, BAI S. Correlation analysis of antinuclear antibody profile expression with HCV-RNA load and HCV genotype in patients with chronic hepatitis C[J]. J Clin Transfus Lab Med, 2022, 24(6):767-772. doi:10.3969/j.issn.1671-2587.2022.06.017.
[10]	杨自力, 张任飞, 何欣. HCV基因分型、AFP-L3与P53抗体联合检测在HCV相关肝细胞癌中的诊断价值[J]. 临床肝胆病杂志, 2020, 36(10):2226-2229.
	YANG Z L, ZHANG R F, HE X. Value of combined determination of hepatitis C virus genotype,AFP-L3,and P53 antibody in the diagnosis of hepatitis C virus-related hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(10):2226-2229. doi:10.3969/j.issn.1001-5256.2020.10.013.
[11]	FAN Z, ZHANG Q, CHEN H, et al. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes[J]. Microb Pathog, 2017, 112:320-326. doi:10.1016/j.micpath.2017.10.003.
[12]	李昕, 冯瑾, 关兴, 等. 血浆miR-21,miR-155水平对胰腺癌的诊断价值[J]. 中国医药导报, 2020, 17(20):21-24.
	LI X, FENG J, GUAN X, et al. Diagnostic value of plasma miR-21 and miR-155 levels in pancreatic cancer[J]. China Medical Herald, 2020, 17(20):21-24.
[13]	崔立华, 李杨, 白晶, 等. 血清miR-122和miR-155在丙戊酸钠诱导小鼠仔鼠肝损伤中的表达[J]. 天津医药, 2021, 49(6):593-597.
	CUI L H, LI Y, BAI J, et al. The expression of serum miR-122 and miR-155 in liver injury induced by valproate in mouse offspring[J]. Tianjin Med J, 2021, 49(6):593-597. doi:10.11958/20202948.
[14]	FENG X, BAO J, SONG C, et al. Functional role of miR-155 in physiological and pathological processes of liver injury(Review)[J]. Mol Med Rep, 2021, 24(4):714. doi:10.3892/mmr.2021.12353.
[15]	JIN X, ZHANG Y, WANG H, et al. Expression and clinical values of serum miR-155 and miR-224 in Chinese patients with HCV infection[J]. Int J Gen Med, 2022, 15:1393-1403. doi:10.2147/IJGM.S344345.
[16]	杜斌, 夏奇奂, 卢跃, 等. 血清微小RNA-155-5p对脓毒症急性肝损伤患者预后的评估价值分析[J]. 中国医师进修杂志, 2020, 43(5):397-400.
	DU B, XIA Q H, LU Y, et al. Predictive value of serum microRNA-155-5p on prognosis in sepsis patients with acute liver injury[J]. Chinese Journal of Postgraduates of Medicine, 2020, 43(5):397-400. doi:10.3760/cma.j.cn115455-20191125-00960.
[17]	BULFONI M, PRAVISANI R, DALLA E, et al. miRNA expression profiles in liver grafts of HCV and HIV/HCV-infected recipients,6 months after liver transplantation[J]. J Med Virol, 2021, 93(8):4992-5000. doi:10.1002/jmv.26999.
[18]	杨屹立, 何学元, 潘新民, 等. miR-205-5p抑制体外胃癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(8):1068-1075.
	YANG Y L, HE X Y, PAN X M, et al. miR-205-5p inhibits proliferation,migration and invasion of gastric cancer cell lines[J]. Basic & Clinical Medicine, 2020, 40(8):1068-1075. doi:10.16352/j.issn.1001-6325.2020.08.011.
[19]	乔会格, 朱康宁. 肝癌患者血清miR-122-5p miR-205-5p miR-486-5p的表达及临床意义[J]. 临床心身疾病杂志, 2020, 26(3):11-15.
	QIAO H G, ZHU K N. Expression and clinical significance of serum miR-122-5p,miR-205-5p and miR-486-5p in patients with liver cancer[J]. J Clin Psychosom Dis, 2020, 26(3):11-15. doi:10.3969/j.issn.1672-187X.2020.03.003.
[20]	LIU G, YANG Z F, SUN J, et al. The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth[J]. Cell Oncol(Dordr), 2022, 45(6):1435-1449. doi:10.1007/s13402-022-00730-4.
[21]	FANG L, WANG H F, CHEN Y M, et al. Baicalin confers hepatoprotective effect against alcohol-associated liver disease by upregulating microRNA-205[J]. Int Immunopharmacol, 2022,107:108553. doi:10.1016/j.intimp.2022.108553.

组别	n		男性	年龄/岁		BMI/（kg/m²）		LDL-C/（mmol/L）		HDL-C/（mmol/L）		WBC/（×10⁹/L）		RBC/（×10¹²/L）
对照组	141		76（53.9）	46.34±8.64		23.29±2.26		2.35±0.36		1.24±0.32		6.24±1.49		5.43±1.23
非HCV-1b组	49		28（59.2）	47.57±8.92		23.70±2.31		2.41±0.43		1.26±0.34		6.12±1.46		5.21±1.16
HCV-1b组	92		53（57.6）	46.86±8.37		23.41±2.15		2.37±0.52		1.23±0.31		6.51±1.53		5.64±1.35
χ²或F			0.362	0.389		0.614		0.357		0.140		1.367		1.946
组别		ALT/（U/L）			AST/（U/L）		LDH/（U/L）		ALB/（g/L）		TBIL/（μmol/L）		GLU/（mmol/L）
对照组		27.26±6.91			22.44±5.62		184.61±31.33		45.12±11.33		6.26±1.52		5.46±1.03
非HCV-1b组		48.22±10.35^a			35.26±11.37^a		186.42±30.76		38.32±9.25^a		10.16±3.58^a		5.14±1.01
HCV-1b组		50.17±12.51^a			37.35±11.62^a		190.37±34.21		41.21±10.36^a		10.32±3.64^a		5.22±1.06
F		187.127^＊＊			87.195^＊＊		0.895		8.628^＊＊		73.596^＊＊		2.448

组别	n		男性	年龄/岁		BMI/（kg/m²）		LDL-C/（mmol/L）		HDL-C/（mmol/L）		WBC/（×10⁹/L）		RBC/（×10¹²/L）
对照组	141		76（53.9）	46.34±8.64		23.29±2.26		2.35±0.36		1.24±0.32		6.24±1.49		5.43±1.23
非HCV-1b组	49		28（59.2）	47.57±8.92		23.70±2.31		2.41±0.43		1.26±0.34		6.12±1.46		5.21±1.16
HCV-1b组	92		53（57.6）	46.86±8.37		23.41±2.15		2.37±0.52		1.23±0.31		6.51±1.53		5.64±1.35
χ²或F			0.362	0.389		0.614		0.357		0.140		1.367		1.946
组别		ALT/（U/L）			AST/（U/L）		LDH/（U/L）		ALB/（g/L）		TBIL/（μmol/L）		GLU/（mmol/L）
对照组		27.26±6.91			22.44±5.62		184.61±31.33		45.12±11.33		6.26±1.52		5.46±1.03
非HCV-1b组		48.22±10.35^a			35.26±11.37^a		186.42±30.76		38.32±9.25^a		10.16±3.58^a		5.14±1.01
HCV-1b组		50.17±12.51^a			37.35±11.62^a		190.37±34.21		41.21±10.36^a		10.32±3.64^a		5.22±1.06
F		187.127^＊＊			87.195^＊＊		0.895		8.628^＊＊		73.596^＊＊		2.448

组别	n	miR-155	miR-205-5p
对照组	141	1.01±0.19	1.02±0.21
非HCV-1b组	49	2.04±0.54^a	0.66±0.14^a
HCV-1b组	92	2.82±0.77^ab	0.51±0.13^ab
F		356.215^＊＊	249.885^＊＊

组别	n	miR-155	miR-205-5p
对照组	141	1.01±0.19	1.02±0.21
非HCV-1b组	49	2.04±0.54^a	0.66±0.14^a
HCV-1b组	92	2.82±0.77^ab	0.51±0.13^ab
F		356.215^＊＊	249.885^＊＊

肝炎活动度分级	n	miR-155	miR-205-5p
G0级	23	1.87±0.27	0.78±0.15
G1级	33	2.34±0.31^a	0.67±0.13^a
G2级	38	2.56±0.32^ab	0.55±0.11^ab
G3级	27	2.86±0.35^abc	0.43±0.11^abc
G4级	20	3.22±0.37^abcd	0.32±0.09^abcd
F		56.450^＊＊	54.424^＊＊